Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries UNITY Biotechnology to Participate in the SVB Securities Global Biopharma Conference By: Unity Biotechnology, Inc. via GlobeNewswire February 15, 2023 at 08:00 AM EST SOUTH SAN FRANCISCO, Calif., Feb. 15, 2023 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (“UNITY”) [NASDAQ: UBX], a biotechnology company developing therapeutics to slow, halt, or reverse diseases of aging, today announced that the Company’s Management will provide a corporate update and participate in one-on-one investor meetings at the SVB Securities Global Biopharma Conference on Wednesday, February 15, 2023 at 11:20 AM ET. The webcast of the presentation will be accessible here and through the “Investors and Media” section of our website, www.unitybiotechnology.com, under “Events & Presentations.” About UNITYUNITY is developing a new class of therapeutics to slow, halt or reverse diseases of aging. UNITY’s current focus is on creating medicines to selectively eliminate or modulate senescent cells and thereby provide transformative benefit in age-related ophthalmologic and neurologic diseases. More information is available at www.unitybiotechnology.com or follow us on Twitter and LinkedIn. Media Contact Evoke Canale Katherine Smith Katherine.smith@evokegroup.com Investor Contact LifeSci Advisors, LLC Joyce Allaire jallaire@lifesciadvisors.com Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
UNITY Biotechnology to Participate in the SVB Securities Global Biopharma Conference By: Unity Biotechnology, Inc. via GlobeNewswire February 15, 2023 at 08:00 AM EST SOUTH SAN FRANCISCO, Calif., Feb. 15, 2023 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (“UNITY”) [NASDAQ: UBX], a biotechnology company developing therapeutics to slow, halt, or reverse diseases of aging, today announced that the Company’s Management will provide a corporate update and participate in one-on-one investor meetings at the SVB Securities Global Biopharma Conference on Wednesday, February 15, 2023 at 11:20 AM ET. The webcast of the presentation will be accessible here and through the “Investors and Media” section of our website, www.unitybiotechnology.com, under “Events & Presentations.” About UNITYUNITY is developing a new class of therapeutics to slow, halt or reverse diseases of aging. UNITY’s current focus is on creating medicines to selectively eliminate or modulate senescent cells and thereby provide transformative benefit in age-related ophthalmologic and neurologic diseases. More information is available at www.unitybiotechnology.com or follow us on Twitter and LinkedIn. Media Contact Evoke Canale Katherine Smith Katherine.smith@evokegroup.com Investor Contact LifeSci Advisors, LLC Joyce Allaire jallaire@lifesciadvisors.com
SOUTH SAN FRANCISCO, Calif., Feb. 15, 2023 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (“UNITY”) [NASDAQ: UBX], a biotechnology company developing therapeutics to slow, halt, or reverse diseases of aging, today announced that the Company’s Management will provide a corporate update and participate in one-on-one investor meetings at the SVB Securities Global Biopharma Conference on Wednesday, February 15, 2023 at 11:20 AM ET. The webcast of the presentation will be accessible here and through the “Investors and Media” section of our website, www.unitybiotechnology.com, under “Events & Presentations.” About UNITYUNITY is developing a new class of therapeutics to slow, halt or reverse diseases of aging. UNITY’s current focus is on creating medicines to selectively eliminate or modulate senescent cells and thereby provide transformative benefit in age-related ophthalmologic and neurologic diseases. More information is available at www.unitybiotechnology.com or follow us on Twitter and LinkedIn. Media Contact Evoke Canale Katherine Smith Katherine.smith@evokegroup.com Investor Contact LifeSci Advisors, LLC Joyce Allaire jallaire@lifesciadvisors.com